Acadia Pharmaceuticals Receivables

Acadia Pharmaceuticals (ACAD) currently reports a receivables of $170M as of June 2026. That compares with $120M in the prior-year period — up 39.0% year over year. Use the charts on this page to explore Acadia Pharmaceuticals's receivables history and peer comparisons.

Acadia Pharmaceuticals's receivables increased from $120M to $170M — a 39.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Acadia Pharmaceuticals reported $170M in receivables as of June 2026. That compares with $120M in the prior-year period — up 39.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $170M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Acadia Pharmaceuticals, and consider following ACAD for alerts when major investors trade the stock.

Acadia Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $170M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ACAD with unrelated industries.